Percheron Therapeutics has announced that it will investigate avicursen (ATL1102) in other indications besides Duchenne muscular dystrophy (DMD) following disappointing Phase IIb results last month.

Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Percheron Therapeutics has reported a significant change in its substantial shareholding, as Platinum Investment ...

The artery of Percheron is a rare anatomical variation that supplies thalamus and the midbrain. A stroke in this area is a rare event. The presentation varies widely, with some bizarre disturbances, ...

Diffusion-weighted imaging (DWI) sequences revealed the presence of recent ischaemic lesions in the territory of the artery of Percheron (AOP), involving the bilateral ventral thalamus portion and ...

Objectives To present a case of bilateral thalamic ischaemic strokes in an elderly gentleman due to occlusion of the artery of Percheron, a rare anatomical variant in which a single branch of the ...

DMD occurs in approximately one in every 3,500 male births. Credit: Dan76 / Shutterstock. Percheron Therapeutics has announced that it will investigate avicursen (ATL1102) in other indications besides ...